<scp>LOPP</scp> chemotherapy as a first‐line treatment for dogs with T‐cell lymphoma

Brown, Paul; Tzannes, Sophia; Nguyen, Sandra; White, Jo; Langova, V.

doi:10.1111/vco.12318

Cited by 40 publications

(63 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These survival times are longer than any previously published on dogs with T cell lymphoma. Brown et al performed a similar study investigating the use of a modified LOPP protocol in 31 dogs and found a median disease‐free interval of 176 days (range 0‐1745) and MST of 323 days (range 51‐1758). The current study found increased survival times using a similar LOPP based protocol as the one used in Brown's study, compared with older protocols.…”

Section: Discussionmentioning

confidence: 99%

“…The current study had a 2‐year PFS of 29%. Other papers reported 2‐year survival rates, Brown et al had 25% and Goodman et al had 20% and Brodsky et al had 25% of dogs alive at 939 days (2.5 years) …”

Section: Discussionmentioning

confidence: 99%

“…Protocols investigated include L‐asparaginase and MOPP, vincristine, L‐asparaginase, cyclophosphamide, lomustine, doxorubicin, prednisolone, procarbazine and mechlorethamine (VELCAP‐TSC) and lomustine, vincristine, procarbazine and prednisolone (LOPP). These studies found improved overall MST ranging from 237 to 323 days …”

Section: Introductionmentioning

confidence: 92%

See 2 more Smart Citations

Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs

Morgan

O’Connell

Thomson

et al. 2018

Vet Comparative Oncology

View full text Add to dashboard Cite

Canine T cell lymphoma has previously been found to be a poor prognostic indicator compared with its B cell counterpart. The cyclophosphamide, doxorubicin, vincristine, and prednisolone protocol is widely accepted as a first line treatment for canine lymphoma. There have been several studies investigating alternative protocols for T cell lymphoma. This study investigated the use of a modified lomustine, vincristine, procarbazine and prednisolone protocol as a first line treatment in 35 dogs with T Cell lymphoma. Median progression free survival (PFS) time for all 35 dogs was 431 days with a 6-month, 1-year, 2-year, and 3-year PFS of 69%, 54%, 29%, and 12%. Median survival time (MST) was 507 days. Twenty-nine dogs attained a complete response and had a median PFS time of 509 days. Thirty dogs experienced adverse events during the protocol, with 73% of these being grade 1 or 2. This protocol has shown increased median PFS time and MST compared with previous studies and suggests its use as a first line chemotherapy protocol against canine T cell lymphoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs

Morgan

O’Connell

Thomson

et al. 2018

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…).The high‐grade T‐cell form may carry a worse prognosis although newer protocols rich in alkylating agents have demonstrated comparable survival times (Brown et al . ). However, extranodal lymphoma such as hepatic, hepatosplenic and gastrointestinal are less frequently described in the dog; these are mainly T‐cell tumours and often associated with poor outcome (Frank et al .…”

Section: Introductionmentioning

confidence: 97%

Clinical characteristics and outcome of dogs with presumed primary renal lymphoma

Taylor

Finotello

Saavedra

et al. 2019

J of Small Animal Practice

View full text Add to dashboard Cite

Objectives To characterise the presentation, clinicopathologic data and outcome of 29 dogs with presumed primary renal lymphoma. Materials and Methods Retrospective analysis of medical records of dogs with suspected primary renal lymphoma from 11 institutions. Results All dogs were substage b, and lethargy and gastrointestinal signs were common presenting complaints, as were azotaemia (n=25; 86%) and erythrocytosis (n=15; 51%) on biochemical testing. Ultrasonography typically revealed bilateral renal lesions (n=23; 79%), renomegaly (n=22; 76%) and abdominal lymphadenopathy (n=14; 48%). Chemotherapy was the only treatment in 23 dogs, of which 11 responded, all considered partial responses. For all dogs the median progression‐free survival and median overall survival times were 10 days (range: 1 to 126) and 12 days (range: 1 to 212), respectively, and for dogs that responded to chemotherapy 41 days (range: 10 to 126) and 47 days (range: 10 to 212), respectively. Clinical Significance Primary renal lymphoma in dogs appears to be associated with a poor prognosis and short‐lived response to chemotherapy.

show abstract

“…CHOP) for DLBCL and lomustine‐based protocols (LOP or LOPP) for treatment of high grade T cell lymphoma, although no randomised clinical studies have been conducted to support this approach (Brown et al . , Morgan et al . ).…”

Section: Introductionmentioning

confidence: 99%

Significant advances in veterinary oncology – 60 years on

Dobson

2019

J of Small Animal Practice

View full text Add to dashboard Cite

The first edition of the Journal of Small Animal Practice published in February 1960, contained a paper entitled “Recent Treatments of Malignant Neoplasia” by Dr Larry Owen. Now we have reached the 60th anniversary of JSAP, that article provides a baseline from which to review subsequent advances in veterinary oncology, which now includes worldwide networks that have resulted in veterinary oncology becoming the multidisciplinary speciality that it is today. There certainly have been many advances in understanding of the pathology and epidemiology of animal cancers and in methods of diagnosis and treatment. However, the subject has become so large and diverse that not all aspects can be covered in detail here. It should also be acknowledged that there are still many gaps in knowledge in this field and that, because of a lack of randomised clinical trials, the evidence base for what is often regarded as “standard of care” is weak.

show abstract

LOPP chemotherapy as a first‐line treatment for dogs with T‐cell lymphoma

Abstract: LOPP chemotherapy for T cell lymphoma is well tolerated with a low toxicity profile and an excellent overall response rate. This protocol showed minimal toxicity and comparable disease free interval and survival times for canine high grade T cell lymphoma treated with CHOP.

Cited by 40 publications

References 20 publications

Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs

Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs

Clinical characteristics and outcome of dogs with presumed primary renal lymphoma

Significant advances in veterinary oncology – 60 years on

Contact Info

Product

Resources

About